Source access required
CVR360 has not loaded official Danish source data for this company yet. No AI or financial conclusion is generated without source-backed facts.
AT
Analona Therapeutics ApS
aktivCVR 44958821AnpartsselskabHerningvej 34, 4800 Nykøbing FForskning og eksperimentel udvikling inden for naturvidenskab og teknik
- Latest accounts
- 2025
- Statement scope
- Standalone
- Verified
- 05 Nov 2026
- Sources
- 5
What changed?
Source-backed changes, not an assessment.
1 source
Key figures
Latest period: 2025
Revenue
Not available from the published filing—
Not available from the published filing
Operating profit
DKK -58.1k
Latest period
Source details
Source: dk-regnskabsdata-live-44958821-1793906104773
Document: dk-regnskabsdata-44958821-AZ8Ae6f1Y4y0EUXks5rR-1
XBRL: d:ProfitLossFromOrdinaryOperatingActivities
Period: 09 Jul 2024 - 31 Dec 2025
Technical details
Context: c1
Unit: u3
Net result
DKK -896.9k
Latest period
Source details
Source: dk-regnskabsdata-live-44958821-1793906104773
Document: dk-regnskabsdata-44958821-AZ8Ae6f1Y4y0EUXks5rR-1
XBRL: d:ProfitLoss
Period: 09 Jul 2024 - 31 Dec 2025
Technical details
Context: c1
Unit: u3
Equity
DKK -856.9k
Equity ratio: -18.7%
Source details
Source: dk-regnskabsdata-live-44958821-1793906104773
Document: dk-regnskabsdata-44958821-AZ8Ae6f1Y4y0EUXks5rR-1
XBRL: d:Equity
Period: 09 Jul 2024 - 31 Dec 2025
Technical details
Context: c45
Unit: u3
Development
Reported values. Missing periods appear as gaps.
RevenueNet result
Tabular view of development
| Year | Revenue | Net result |
|---|---|---|
| 2025 | — | DKK -896.9k |